Form 4: Apellis Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Apellis Pharmaceuticals' Chief Development Officer, Jeffrey Eisele, sold 278 shares of common stock to cover tax obligations related to released Restricted Stock Units.

Summary

• Jeffrey Eisele, Chief Development Officer at Apellis Pharmaceuticals, sold 278 shares of common stock on January 29, 2025.
• The sale was executed at a price of $29.5236 per share.
• This transaction was to cover tax withholding obligations related to Restricted Stock Units that vested on January 28, 2025.
• Following the transaction, Mr. Eisele directly owns 55,312 shares of Apellis Pharmaceuticals stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no significant positive or negative implications for the company's performance or outlook.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the pharmaceutical industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar tax-related sales by executives at other firms.
• Comparable companies such as Regeneron, Biogen, and Vertex Pharmaceuticals also see similar transactions by their executives.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale for tax purposes.

Key Dates

Keywords

Apellis Pharmaceuticals, Jeffrey Eisele, stock sale, insider trading, Form 4, tax withholding, restricted stock units, APLS